Suchergebnisse - (Person:"Mo, Hongnan")

PubPharm (11)

1

Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer : A prospective study

enthalten in: Thoracic cancer | 2024

von Wu, Y. | Mo, H. | Xu, H. | +4

2

MTA1, a Novel ATP Synthase Complex Modulator, Enhances Colon Cancer Liver Metastasis by Driving Mitochondrial Metabolism Reprogramming

enthalten in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2023

von Wang, T. | Sun, F. | Li, C. | +12

3

Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer

enthalten in: JAMA network open | 2022

von Mo, H. | Yan, X. | Zhao, F. | +11

4

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

enthalten in: Cancer cell | 2021

von Zhang, Y. | Chen, H. | Mo, H. | +17

CommentIn: Cancer Cell. 2021 Dec 13;39(12):1562-1564. - PMID 34767761

5

The molecular tumor burden index as a response evaluation criterion in breast cancer

enthalten in: Signal transduction and targeted therapy | 2021

von Yi, Z. | Ma, F. | Rong, G. | +10

6

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody

enthalten in: Thoracic cancer | 2019

von Wang, X. | Zhang, B. | Chen, X. | +6

7

Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials : a cross-sectional study in China

enthalten in: BMJ open | 2019

von Jiang, S. | Liu, P. | Yang, S. | +15

8

Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China

enthalten in: Cancer | 2019

von Huang, J. | Mo, H. | Zhang, W. | +12

9

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours : a dose-escalation, phase 1 study

enthalten in: British journal of cancer | 2018

von Mo, H. | Huang, J. | Xu, J. | +11

10

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Huang, J. | Xu, B. | Mo, H. | +11